OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals.
Alyssa YlescupidezCate SpeakeSusan L PietropaoloDarrell M WilsonAndrea K SteckJennifer L SherrJason L GagliaChristine BenderSandra M LordCarla J GreenbaumPublished in: The Journal of clinical endocrinology and metabolism (2023)
Every six-month CGM measures in multiple-AAB-positive individuals are predictive of subsequent T1D, but less so than OGTT derived variables. CGM may have feasibility advantages and be useful in some settings. However, our data suggests there is insufficient evidence to replace OGTT measures with CGM in the context of clinical trials.